Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy

He CHEN; Juanjuan FU; Li LI; Guangde YANG; Xiucheng PAN

doi:10.3969/j.issn.1001-5256.2021.03.011

Volume 37 Issue 3

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(3): 556-559

PDF( 1808 KB)

Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2021.03.011

Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China

Received Date: 2020-09-12
Accepted Date: 2020-10-06
Published Date: 2021-03-20

Abstract

Abstract

Objective To investigate the influencing factors for persistent low-level viremia (LLV) in chronic hepatitis B(CHB) patients receiving long-term entecavir antiviral therapy. Methods The CHB patients who received entecavir antiviral therapy for at least one year in The Affiliated Hospital of Xuzhou Medical University from November 2018 to June 2020 were enrolled as subjects, and according to HBV DNA load at the end of the observation period, the patients were divided into LLV group and sustained virological response (SVR) group. Demographic features and laboratory markers were observed for all patients. The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. A multivariate logistic regression analysis was used to investigate the influencing factors for LLV in patients receiving long-term entecavir treatment. Results A total of 560 CHB patients were enrolled, with 204 in the LLV group and 356 in the SVR group. There were significant differences between the two groups in age (Z=-3.530, P < 0.001), sex (χ²=4.270, P=0.039), presence or absence of liver cirrhosis (χ²=53.879, P < 0.001), medication compliance (χ²=5.326, P=0.021), HBeAg positive rate (χ²=90.681, P < 0.001), baseline HBV DNA load before treatment (Z=-8.337, P < 0.001), baseline HBsAg quantification (Z=-10.472, P < 0.001), and medication type (χ²=7.558, P=0.006). The multivariate logistic regression analysis showed that baseline HBeAg status before treatment (odds ratio [OR]=3.381, 95% confidence interval [CI]: 1.985-5.756, P < 0.001), HBV DNA load before treatment (OR=1.223, 95%CI: 1.050-1.424, P=0.010), and HBsAg quantification before treatment (OR=2.448, 95%CI: 1.743-3.438, P < 0.001) were risk factors for LLV in long-term entecavir antiviral therapy. Conclusion In clinical practice, CHB patients with high HBV DNA load, high HBsAg quantification, and positive HBeAg tend to have a high risk of LLV even after long-term entecavir antiviral therapy. Therefore, such population should be taken seriously with the dynamic monitoring of HBsAg quantification, HBV DNA load, and HBeAg status.
- Hepatitis B, Chronic,
- Low-Level Viremia,
- Entecavir,
- Risk Factors

FullText(HTML)

References(18)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
[2]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800
[3]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021
[4]	OGAWA E, NOMURA H, NAKAMUTA M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020, 40(7): 1578-1589. DOI: 10.1111/liv.14482
[5]	KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916
[6]	LU JH, YANG L, ZHAO ZX, et al. Comparative study of high-sensitivity and ordinary fluorescence quantitative PCR in monitoring antiviral efficacy of patients with chronic hepatitis B[J]. J Mol Diagn Ther, 2019, 11(5): 361-364. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YXYQ201905004.htm 卢建华, 杨莉, 赵召霞, 等. 高敏与普通荧光定量PCR技术在慢乙肝患者抗病毒疗效监测中的对比研究[J]. 分子诊断与治疗杂志, 2019, 11(5): 361-364. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYQ201905004.htm
[7]	KIM HJ, CHO YK, JEON WK, et al. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience[J]. Clin Mol Hepatol, 2017, 23(4): 323-330. DOI: 10.3350/cmh.2017.0005
[8]	HUANG YJ, YANG SS, YEH HZ, et al. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B[J]. PLoS One, 2019, 14(8): e0221958. DOI: 10.1371/journal.pone.0221958
[9]	SUN Y, WU X, ZHOU J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591. DOI: 10.1016/j.cgh.2020.03.001
[10]	SHIN JW, JUNG SW, LEE SB, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir[J]. Am J Gastroenterol, 2018, 113(7): 998-1008. DOI: 10.1038/s41395-018-0093-9
[11]	LIN L, LIU JY, DENG H, et al. Influencing factors of partial virological response to entecavir monotherapy of patients with chronic hepatitis B[J/CD]. Chin J Liver Dis (Electronic Version), 2019, 11(4): 81-84. (in Chinese) 林丽, 刘俊英, 邓慧, 等. 恩替卡韦单药治疗慢性乙型肝炎患者部分病毒学应答的影响因素[J/CD]. 中国肝脏病杂志(电子版), 2019, 11(4): 81-84.
[12]	GORDON SC, KRASTEV Z, HORBAN A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load[J]. Hepatology, 2013, 58(2): 505-513. DOI: 10.1002/hep.26277
[13]	QIU Q, YU HY, PAN J, et al. Antiviral efficacy of entecavir for the treatment of chronic hepatitis B[J]. J Southeast Univ (Med Sci Edi), 2010, 29(6): 685-688. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-NJTD201006025.htm 裘强, 俞海英, 潘剑, 等. 恩替卡韦治疗慢性乙型肝炎疗效观察[J]. 东南大学学报(医学版), 2010, 29(6): 685-688. https://www.cnki.com.cn/Article/CJFDTOTAL-NJTD201006025.htm
[14]	HE LF, LONG YS, ZHANG HY. Correlation study between hepatitis B virus DNA replication level and HBeAg and HBsAg[J]. Clin Med Eng, 2020, 27(1): 65-66. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YBQJ202001033.htm 何龙芳, 龙云升, 张海业. 乙型肝炎病毒DNA复制水平与HBeAg、HBsAg的相关性研究[J]. 临床医学工程, 2020, 27(1): 65-66. https://www.cnki.com.cn/Article/CJFDTOTAL-YBQJ202001033.htm
[15]	LEE JM, AHN SH, KIM HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir[J]. Hepatology, 2011, 53(5): 1486-1493. DOI: 10.1002/hep.24221
[16]	CHANG ML, CHIEN RN, YEH CT, et al. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B[J]. J Hepatol, 2005, 43(1): 72-77. DOI: 10.1016/j.jhep.2005.02.021
[17]	ZHANG N. The clinical significance of HBsAg quantitative level in HBeAg-negative patients with chronic HBV infection[D]. Yan'an: Yan'an University, 2020. (in Chinese) 张楠. HBsAg定量水平在HBeAg阴性慢性HBV感染者中的临床意义[D]. 延安: 延安大学, 2020.
[18]	SONG JC, MIN BY, KIM JW, et al. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B[J]. Korean J Hepatol, 2011, 17(4): 268-273. DOI: 10.3350/kjhep.2011.17.4.268

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(20)

1.	孔宁. 慢性乙型病毒性肝炎患者经恩替卡韦治疗后发生低病毒血症的影响因素. 中国民康医学. 2025(04): 16-19 .
2.	张祥运，马序竹，于国英. 慢性乙型肝炎患者低病毒血症影响因素及管理策略研究. 肝脏. 2024(02): 247-250 .
3.	向文耀，李仕雄，吕日英. 恩替卡韦治疗后慢性乙型肝炎低病毒血症患者序贯联合艾米替诺福韦治疗的效果研究. 中国现代医学杂志. 2024(08): 15-20 .
4.	张万洁，李子怡，王富春，田爱平，毛小荣. 抗病毒治疗的慢性乙型病毒性肝炎患者低病毒血症影响因素分析. 山东医药. 2024(08): 68-71 .
5.	谢露，刘亚楠，刘光伟，李鹏宇，胡新宁，康秋佳，郭会军. 经治慢性乙型肝炎患者低病毒血症发生率和影响因素的Meta分析. 临床肝胆病杂志. 2024(07): 1334-1342 . 本站查看
6.	张沙沙，赵迎春，周红霞. 恩替卡韦经治乙肝肝硬化患者低病毒血症对肝癌发病的影响. 临床荟萃. 2024(11): 980-983 .
7.	孟娟，孙密密. 慢性乙型肝炎低病毒血症的研究现状. 传染病信息. 2024(06): 550-554 .
8.	刘硕，邱兴迪，吴品. 补肾健脾汤联合恩替卡韦治疗慢性乙型肝炎的疗效研究. 实用中西医结合临床. 2024(23): 12-14+102 .
9.	杨雪，曹利锋. 艾米替诺福韦降低经治慢性乙型肝炎患者HBV DNA水平1例. 中华肝脏病杂志. 2024(S1): 81-82 .
10.	刘智泓，梁携儿，侯金林. 关于《扩大慢性乙型肝炎抗病毒治疗的专家意见》的几点思考. 临床肝胆病杂志. 2023(01): 14-21 . 本站查看
11.	李彤，孔银，刘元元，刘天府，麻爱娣，李龙泉，裴志燕，张岭漪. 经治慢性乙型肝炎低病毒血症患者人群特征及其相关影响因素：一项单中心横断面回顾性研究. 中华肝脏病杂志. 2023(01): 42-48 .
12.	杨雪芳，胥莹，张帮婷，张雪. 经治慢性乙型肝炎患者低病毒血症的临床特征及危险因素分析. 胃肠病学和肝病学杂志. 2023(03): 276-281 .
13.	黄永栩，陈超，保紫红，周小辉. 恩替卡韦治疗的慢性乙型肝炎患者低病毒血症的影响因素. 肝脏. 2023(03): 320-324 .
14.	方木林，周利民. 淳安县慢性乙型肝炎患者对疾病防治知识的认知情况及影响因素分析. 健康研究. 2022(04): 395-398 .
15.	解洪银，鲁晓岚. 恩替卡韦经治慢性乙肝患者低病毒血症的临床研究进展. 复旦学报(医学版). 2022(05): 777-782 .
16.	宣碧碧，徐永红，杜忠彩，刘玉，杨玉玲，边城. 慢性乙型肝炎和乙型肝炎肝硬化患者发生低病毒血症的影响因素及其与肝脏炎症、肝纤维化进展的关系o-展. 临床肝胆病杂志. 2022(10): 2252-2259 . 本站查看
17.	梁学龙，穆凯，蔡尚原. 恩替卡韦与阿德福韦酯对慢性乙型肝炎患者肝功能及APRI、FIB-4、RPR的影响. 临床医学研究与实践. 2022(32): 59-61 .
18.	夏盼盼，颜成果，郭心阳，闪海霞. 干扰素α-2b联合恩替卡韦治疗慢性乙型肝炎患者的效果. 中国民康医学. 2022(21): 38-40 .
19.	程齐齐，杨丽霞，蔡天盼，王亮，孙俊，梁佳圆，刘丽萍，甘厦，阮宁杭，葛善飞. 核苷（酸）类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析. 临床肝胆病杂志. 2022(12): 2716-2722 . 本站查看
20.	王玉珊，张岭漪. 不同转换策略对慢性乙型肝炎低病毒血症疗效的临床研究. 胃肠病学. 2022(02): 115-118 .

Other cited types(10)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (902) PDF downloads(151)

Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2021.03.011